Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.
Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian M-A, Henry D, Akbari Sari A
Daru. 2013; 21(1):50. Epub 2013 Jun 22. PMID: 23800250.Abstract